Products of interest

Founding Directors

Medical Information

Track Record

Sinepin (Doxepin) from Pfizer UK December 2006

Dermacort (Hydrocortisone) from Stada (Genus Pharmaceuticals) August 2006

Gygel (Nonoxinol-9) from Janssen-Cilag January 2008

Anacal (Heparinoid) from Stada (Genus Pharmaceuticals) May 2008

Gynest Cream (Estriol 0.01% Estriol) from Janssen-Cilag January 2010

Welldorm Tablets and Elixir from Alphashow May 2011

Products of Interest

Marlborough wishes to acquire and commercially develop niche pharmaceuticals
The products will ideally be used in hospitals or have a hospital led prescription base
The products are unlikely to have generic competition
End stage treatments are of special interest
Products should have a major use in the UK

Business Development

Marlborough Pharmaceuticals has considerable experience, having already made a series of acquisitions from top 20 pharmaceutical companies and is highly regarded as a "safe pair of hands."

Marlborough Pharmaceuticals has been highly successful in rapid regulatory approval of product changes.

Marlborough Pharmaceuticals has a range of business agreements in place including:

- Contract manufacturing partnerships
- UK distribution partnerships
- Partners in major non UK markets

How the company is financed

Marlborough is privately owned and financed by shareholders' funds, medium term bank funding and income from trading

Lines of credit are available to Marlborough to purchase suitable products

Marlborough will consider all types of deals including acquisition, licensing, hire purchase and fostering agreements

Marlborough is not a drug discovery company but concentrates on maximising returns for all shareholders and patients alike.


	Home	Business Profile	Product Information	Business Development	Recruitment	Contact Us